Cerner RadNet Radiology Information System (RIS) provides the tools to work more efficiently while providing patients with a positive personal experience and delivering superior care.

November 12, 2012 — Cephasonics, Inc., a technology-innovation leader focused on delivering mixed-signal semiconductors, modules and subsystems to the imaging and ultrasound markets, today announced the release of the Cephasonics ultrasound application-programming interface (CS-API) software Version 3.0. Combined with Cephasonics’ Quest™ (CSK9130) front-end beamforming system, it enables OEMs to develop ultrasound-based products for medical and imaging applications quickly and easily. CS-API V3.0 incorporates new and enhanced functions, including parallel beamforming; Doppler modes such as color-flow mapping (CFM), power-Doppler imaging (PDI), and pulsed-wave Doppler (PWD); duplex/triplex modes; and PCI-Express host-interface support. Cephasonics will demonstrate its latest embedded-ultrasound technology at RSNA in Chicago in Hall B, booth 9525, November 25-30.

November 25 — Carestream showed the latest enhancements to its Vue RIS including the storage and tracking of radiation dose information at the Radiological Society of North America (RSNA) tradeshow.

A new statement to help physicians inform women on how breast density affects breast cancer screening and cancer risk has been issued by the American Society of Breast Disease.

In a skeptical world, old maxims fall hard. Photojournalists can attest to that. Seeing today is anything but believing. Not seeing has fallen just as hard. We’d like to know that we can relax when we don’t see signs of cancer’s return. Positron emission tomography/computed tomography (PET/CT) provides that kind of relief in many cases…but not all.

Although it has become the gold standard in oncology diagnosis and monitoring, PET/CT falls short in some cases. And, in those cases, its use can create a false sense of security.

S.M.A.R.T. Control Vascular Stent

fibroglandular densities, dense breasts,
fibroglandular densities, dense breasts,
fibroglandular densities, dense breasts, breast cancer
fibroglandular densities, dense breasts, breast cancer
fibroglandular densities, dense breasts, breast cancer
fibroglandular densities, dense breasts, breast cancer
womens_health_map
Figure 1: Risk level determined by a standardized risk assessment tool.

Since the implementation of routine screening mammography, we have seen a 30 percent reduction in breast cancer mortality. Despite these results, mammography remains at the center of controversy, with seemingly conflicting studies on its effectiveness published on a regular basis.  
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now